Replies to post #9025 on Biotech Values

[DewDiligence]

Re: GTCB

>>I think the chances of EMEA requesting a new study are <25%.<<

What would your guess be?

>>But, I think there is higher chance that some EMEA commisioners want to know how soon the US ATryn could be completed and are going to ask for feasibility or outright demand that approval be deferred until after that study.<<

I do not understand exactly what you mean by this. Please clarify. T.i.a.

p.s. Nice job on your trading acumen.